Cardiovascular protection in the treatment of type 2 diabetes

The various manifestations of atherosclerotic cardiovascular disease are the major cause of mortality in patients with type 2 diabetes. Learn more about management and new therapies with proven cardiovascular safety and benefits.

You will learn:
Atherosclerotic cardiovascular disease (ASCVD) is the major cause of mortality in patients with T2DM
Newly approved glucose-lowering drugs must have undergone cardiovascular outcomes trials to evaluate their cardiovascular safety
Of glucose-lowering drug classes, GLP-1 RAs and SGLT-2 inhibitors are best for reducing cardiovascular risk
Combination therapy with SGLT-2 inhibitors and GLP-1 RAs is being investigated for positive complementary effects.

To access this module, please register or login: